Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME Study: Rituximab for Idiopathic Membranous Nephropathy
NCT05914155Phase 3Active, not recruiting
- Start
- Jun 2023
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in idiopathic membranous nephropathy (IMN). Started Jun 2023; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT05914155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914155.